In particular, our findings of overexpressed CD47 in transcriptomic analysis of patients with EGFR-mutated NSCLC, as well as in tumor cell lines acquiring EGFR TKI resistance, identify CD47 as target to be further explored for the immunotherapy treatment of naïve and resistant EGFR-mutant NSCLCs. This evidence concerns the gene CD47 and non-small cell lung carcinoma.